Currently, atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence of about 2-3% in the general population, representing a powerful risk factor for stroke and systemic thromboembolism and increased mortality and morbidity. Restoration of sinus rhythm is an important treatment option in AF and has a high success rate, but there is the need for an effective anticoagulation strategy to reduce the risk of embolic events. Anticoagulation with vitamin K antagonists is often associated with failure to achieving effective international normalized ratio. In this setting, recent data have led to extended approval for rivaroxaban in clinical practice, because it is effective and safe in patients with AF undergoing cardioversion, avoiding additional health costs and related time loss, while improving patient satisfaction. The present report provides an overview of the main randomized controlled trial and the main real-life studies, documenting the use of rivaroxaban in patients with non-valvular AF who underwent the cardioversion procedure. Considering that novel non-vitamin K antagonist oral anticoagulants in left atrial appendage thrombi resolution is still unknown in the real-world practice, the main findings on the use of rivaroxaban in this setting are also discussed.

Rivaroxaban in atrial fibrillation cardioversion: an update / Lavalle, C.; Straito, M.; Caroli, A.; Piro, A.; Giunta, G.; Mariani, M. V.; Fedele, F.. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 15:(2019), pp. 613-626. [10.2147/TCRM.S201162]

Rivaroxaban in atrial fibrillation cardioversion: an update

Straito M.
Co-primo
;
Caroli A.;Piro A.;Mariani M. V.
Penultimo
;
2019

Abstract

Currently, atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a prevalence of about 2-3% in the general population, representing a powerful risk factor for stroke and systemic thromboembolism and increased mortality and morbidity. Restoration of sinus rhythm is an important treatment option in AF and has a high success rate, but there is the need for an effective anticoagulation strategy to reduce the risk of embolic events. Anticoagulation with vitamin K antagonists is often associated with failure to achieving effective international normalized ratio. In this setting, recent data have led to extended approval for rivaroxaban in clinical practice, because it is effective and safe in patients with AF undergoing cardioversion, avoiding additional health costs and related time loss, while improving patient satisfaction. The present report provides an overview of the main randomized controlled trial and the main real-life studies, documenting the use of rivaroxaban in patients with non-valvular AF who underwent the cardioversion procedure. Considering that novel non-vitamin K antagonist oral anticoagulants in left atrial appendage thrombi resolution is still unknown in the real-world practice, the main findings on the use of rivaroxaban in this setting are also discussed.
2019
atrial fibrillation; cardioversion; novel oral anticoagulants; rivaroxaban; thrombus
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Rivaroxaban in atrial fibrillation cardioversion: an update / Lavalle, C.; Straito, M.; Caroli, A.; Piro, A.; Giunta, G.; Mariani, M. V.; Fedele, F.. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 15:(2019), pp. 613-626. [10.2147/TCRM.S201162]
File allegati a questo prodotto
File Dimensione Formato  
Lavalle_Rivaroxaban_2019.pdf

accesso aperto

Note: https://www.dovepress.com/rivaroxaban-in-atrial-fibrillation-cardioversion-an-update-peer-reviewed-article-TCRM
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 299.46 kB
Formato Adobe PDF
299.46 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1501203
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact